

Neihulizumab

| | |
|-----------|---|
| Cat. No.: | HY-P99378 |
| CAS No.: | 2158362-38-8 |
| Target: | Apoptosis |
| Pathway: | Apoptosis |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | |
|-------------|--|
| Description | Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be used for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research ^[1] . |
| In Vitro | Neihulizumab is a monoclonal antibody against P-selectin glycoprotein ligand-1 (PSGL-1). Neihulizumab binds to human PSGL-1, thereby preferentially inducing apoptosis in late stage activated T cells. At sites of inflammation, the endothelium of blood vessels expresses P-selectin, and activated T cells bind to these sites and migrate through the expression of PSGL-1. In that manner, Neihulizumab is thought to target activated T cells and inhibit trafficking to sites of inflamed tissue ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. Sameem Abedin, et al. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol. 2020 Nov 26;12:549-557.
- [2]. Sameem Abedin, et al. Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD). Blood (2022) 140 (Supplement 1): 10495-10497.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA